On the other hand, we could not detect ASXL1 or RUNX1 mutations in CML patients at initial diagnosis of chronic phase; however, acquisition of RUNX1 and/or ASXL1 mutations occurred in 25.5% (13/51) of patients during AML transformation. The gene discussed is ASXL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.